Rodgau Dudenhofen, Germany
- Featured
Study to evaluate HZN-825 in patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial for HZN-825, a selective antagonist of lysophosphatidic acid receptor-1 (LPAR1). Participants will be screened within 4 weeks prior to the Baseline (Day 1) Visit. Approximately 300 participants who meet the trial eligibility criteria will be randomized on Day 1 in a 1:1:1 ratio to receive HZN-825 300 mg QD, HZN-825 300 mg BID or placebo for 52 weeks. Participants will take their first dose of trial drug at the clinic and will return to the clinic for trial visits at Week 4 and every 6 weeks thereafter until Week 52. Participants who complete the Double-blind Treatment Period (Week 52) may be eligible to enter a 52-week extension trial (HZNP- HZN-825-302). Participants not entering the extension will return to the clinic for a Safety Follow-up Visit 4 weeks after the last dose of trial drug.
Phase
2Span
139 weeksSponsor
Horizon Therapeutics Ireland DACMerida
Recruiting
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
Phase
2Span
135 weeksSponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyMerida
Recruiting
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Phase
3Span
468 weeksSponsor
Regeneron PharmaceuticalsMerida
Recruiting
Merida
Recruiting
Merida, Yucatán
Recruiting
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
Phase
2Span
393 weeksSponsor
Bristol-Myers SquibbMerida
Recruiting
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Phase
3Span
454 weeksSponsor
PfizerMerida, Yucatán
Recruiting
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
The study consists of a 24-week double-blind, placebo control period, a 144-week open-label extension period and follow-up period of 8 weeks after last study drug administration. Eligible participants will be randomized to placebo or nipocalimab (2 dose levels) during the double-blind period and nipocalimab (2 dose levels) during the open-label extension period.
Phase
2/3Span
452 weeksSponsor
Janssen Research & Development, LLCMerida
Recruiting
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Phase
3Span
643 weeksSponsor
Eli Lilly and CompanyMerida, Yucatán
Recruiting
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Phase
3Span
314 weeksSponsor
Eli Lilly and CompanyMerida, Yucatán
Recruiting